Kamada Ltd. - Ordinary Shares (KMDA) analyst actions
Rating and price-target actions on KMDA in the public-source dataset. Wires and filings carry few rating actions, so this list is sparse by nature — the hub's by-event-type table holds the measured analyst base rates. Back to the KMDA overview →
3 measured KMDA analyst action events.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Kamada Announces Discontinuation of its Phase 3 Inhaled AAT Clinical Trial; Reiterates 2025 Full-Year Guidance and Projects Double-Digit Growth in Revenues and Profitability in 2026 | Press release | -0.44% | -0.30% | |
| Kamada Announces First Patient Enrolled into an Investigator-Initiated Clinical Trial of CYTOGAM® to Prevent Cytomegalovirus in Kidney Transplantation | Press release | -0.73% | -3.19% | |
| Kamada Reports Significant Increase in Sales and Profitability in the Third Quarter and Nine Month 2023; Reiterates 2023 Revenue and Profitability Guidance | Press release | -0.21% | +1.70% |
Keep exploring
More KMDA: earnings → · SEC filings → · KMDA overview →
Other Healthcare names and their analyst actions
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| SUNNIVA INC (SNNVF) | 186 | 0.00% | 37% |
| CHOOM HLDGS INC (CHOOF) | 185 | -0.11% | 48% |
| VACCINEX INC (VCNX) | 185 | 0.00% | 48% |
| CONVATEC GRP PLC UNSP/ADR (CNVVY) | 184 | 0.00% | 37% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not. These are each name’s all-news baseline, not its analyst actions — that is what the link opens.